Cargando…

Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis

OBJECTIVE: Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases, ranging from simple steatosis to progressive steatohepatitis and cirrhosis. Because of their anti-inflammatory and anti-fibrotic effects, angiotensin receptor blockers (ARBs) are potential therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yating, Xu, Hong, Wu, Wenrui, Ye, Jianzhong, Fang, Daiqiong, Shi, Ding, Li, Lanjuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Meta-Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963622/ https://www.ncbi.nlm.nih.gov/pubmed/29844879 http://dx.doi.org/10.18632/oncotarget.23816

Ejemplares similares

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cancer risk: an updated meta-analysis of observational studies
por: Shin, Kayeong, et al.
Publicado: (2022)

Effects of adding tripterygium glycosides to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on albuminuria in patients with diabetic nephropathy
por: Fang, Jin-Ying, et al.
Publicado: (2020)

Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach
por: Nixon, R M, et al.
Publicado: (2009)

Relationship between non-alcoholic fatty liver disease and cardiac arrhythmia: a systematic review and meta-analysis
por: Gong, Hang, et al.
Publicado: (2021)

Association of non-alcoholic fatty liver and metabolic-associated fatty liver with COVID-19 outcomes: A systematic review and meta-analysis
por: Jagirdhar, Gowthami Sai Kogilathota, et al.
Publicado: (2023)

Increased risk of cerebrovascular accident related to non-alcoholic fatty liver disease: a meta-analysis
por: Hu, Jianping, et al.
Publicado: (2017)

Meta-analysis reveals up-regulation of cholesterol processes in non-alcoholic and down-regulation in alcoholic fatty liver disease
por: Wruck, Wasco, et al.
Publicado: (2017)

Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis
por: Liu, Jiaye, et al.
Publicado: (2022)

Novel glucose-lowering drugs for non-alcoholic fatty liver disease
por: Fu, Zuo-Di, et al.
Publicado: (2021)

PPAR-alpha/gamma agonists, glucagon-like peptide-1 receptor agonists and metformin for non-alcoholic fatty liver disease: A network meta-analysis
por: Zhang, Zhuo-Ya, et al.
Publicado: (2023)

Application of artificial intelligence in non-alcoholic fatty liver disease and liver fibrosis: a systematic review and meta-analysis
por: Decharatanachart, Pakanat, et al.
Publicado: (2021)

Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors
por: Lee, Terry, et al.
Publicado: (2021)

Renin–angiotensin–aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis
por: Kaur, Upinder, et al.
Publicado: (2021)

Association between non-alcoholic fatty liver disease and risk of incident heart failure: a meta-analysis of observational studies
por: Li, Wensheng, et al.
Publicado: (2022)

Efficacy and safety of semaglutide in non-alcoholic fatty liver disease
por: Zhu, Kai, et al.
Publicado: (2023)

Statin liver safety in non‐alcoholic fatty liver disease: A systematic review and metanalysis
por: Pastori, Daniele, et al.
Publicado: (2021)

Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease
por: Huang, Rong-Shuang, et al.
Publicado: (2016)

Influence of angiotensin converting enzyme inhibitors/angiotensin receptor blockers on the risk of all‐cause mortality and other clinical outcomes in patients with confirmed COVID‐19: A systemic review and meta‐analysis
por: Jia, Na, et al.
Publicado: (2021)

Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis
por: Huang, Yi-Zhou, et al.
Publicado: (2021)

Pre- and post-diagnosis physical activity is associated with survival benefits of colorectal cancer patients: a systematic review and meta-analysis
por: Wu, Wenrui, et al.
Publicado: (2016)

Relationship between total testosterone, sex hormone–binding globulin levels and the severity of non-alcoholic fatty liver disease in males: a meta-analysis
por: Mo, Man-Qiu, et al.
Publicado: (2022)

Protective Effect of Akkermansia muciniphila against Immune-Mediated Liver Injury in a Mouse Model
por: Wu, Wenrui, et al.
Publicado: (2017)

Metabolic benefits of changing sedentary lifestyles in nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials
por: Ma, Qianqian, et al.
Publicado: (2022)

Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis
por: Tang, Yao, et al.
Publicado: (2019)

Vitamin D levels do not predict the stage of hepatic fibrosis in patients with non-alcoholic fatty liver disease: A PRISMA compliant systematic review and meta-analysis of pooled data
por: Saberi, Behnam, et al.
Publicado: (2018)

Hepatitis B virus infection and the risk of nonalcoholic fatty liver disease: a meta-analysis
por: Xiong, Jianping, et al.
Publicado: (2017)

Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis
por: Pan, Lu, et al.
Publicado: (2021)

Meta-analysis reveals gender difference in the association of liver cancer incidence and excess BMI
por: Yao, Kun-Fang, et al.
Publicado: (2017)

Racial disparities in nonalcoholic fatty liver disease clinical trial enrollment: A systematic review and meta-analysis
por: Patel, Parita, et al.
Publicado: (2020)

Systematic review with meta-analysis on transplantation for alcohol-related liver disease: Very low evidence of improved outcomes
por: Shen, Nicole T, et al.
Publicado: (2019)

Effects of intragastric balloon placement in metabolic dysfunction-associated fatty liver disease: A systematic review and meta-analysis
por: de Freitas Júnior, João Remí, et al.
Publicado: (2021)

Ethnic differences in the association between angiotensin-converting enzyme gene insertion/deletion polymorphism and peripheral vascular disease: A meta-analysis
por: Han, Chao, et al.
Publicado: (2017)

Butyrate Protects Mice Against Methionine–Choline-Deficient Diet-Induced Non-alcoholic Steatohepatitis by Improving Gut Barrier Function, Attenuating Inflammation and Reducing Endotoxin Levels
por: Ye, Jianzhong, et al.
Publicado: (2018)

A meta-analysis of the vascular-related safety profile and efficacy of α-adrenergic blockers for symptoms related to benign prostatic hyperplasia
por: Nickel, J C, et al.
Publicado: (2008)

Efficacy of Sodium-Glucose Cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-neprilysin inhibitor: An updated meta-analysis
por: Yamani, Naser, et al.
Publicado: (2021)

An umbrella review and meta‐analysis of renin–angiotensin system drugs use and COVID‐19 outcomes
por: Kurdi, Amanj, et al.
Publicado: (2022)

Alcohol drinking and gastric cancer risk: a meta-analysis of observational studies
por: Wang, Peng-Liang, et al.
Publicado: (2017)

Correlation Between Adiponectin Gene rs1501299 Polymorphism and Nonalcoholic Fatty Liver Disease Susceptibility: A Systematic Review and Meta-Analysis
por: Liu, Jiaxing, et al.
Publicado: (2019)

Pooled analysis of the efficacy and safety of adjunctive alpha-blocker therapy before ureteroscopy in the management of ureteral stones
por: Tan, Hailin, et al.
Publicado: (2020)

Food groups and the likelihood of non-alcoholic fatty liver disease: a systematic review and meta-analysis
por: He, Kaiyin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0ue63mte1fughou68971sq4j7o